Skip to main content

qsymia

Generic: phentermine and topiramate

qsymia: sourced relationships with 1 company · 1 FDA decision.

qsymia evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect qsymia to VVUS; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could qsymia → VVUS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Chronic weight management

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
VIVUS INC (VVUS)
developer · Reported 2020-03-03 · Current development: unknownSource
Chronic weight management
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and incr(VVUS)FDA ↗
NDA022580Type 4 - New CombinationStandardOralCapsule, Extended Release

Frequently asked questions

Which companies have sourced relationships with qsymia?

qsymia has dated SEC/FDA relationship records for VIVUS INC.

What is qsymia's latest FDA decision?

The most recent tracked FDA decision for qsymia is Approval for 1 INDICATIONS AND USAGE QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and incr, dated July 17, 2012.